This model used patients’ longitudinal PSA and biopsy measurements, as well as their Gleason Score at diagnosis, to predict the risk of cancer progression to GG2 or higher upon repeat biopsy through a bivariate joint modeling approach. This evidence concerns the gene KLK3 and cancer.